Zepbound Cost in Tennessee 2026: Pricing, Insurance, and Savings Options

Brand-Name Zepbound: The $1,059 Baseline

Eli Lilly prices Zepbound at a flat $1,059 per month across all dose levels, from the 2.5 mg starter dose through the maximum 15 mg maintenance dose [1]. That price holds at every retail pharmacy in Tennessee, whether you fill at a CVS in Nashville, a Walgreens in Memphis, or an independent pharmacy in Knoxville. No dose-based price tiers exist.

This is the wholesale acquisition cost (WAC), which functions as the sticker price before insurance negotiations. Retail cash-pay prices in Tennessee track this WAC closely, averaging $1,059 per month in 2026. Some pharmacy discount aggregators (GoodRx, RxSaver) may shave $20 to $80 off, but the savings are inconsistent.

For context, Zepbound's pricing sits in line with other branded GLP-1 receptor agonists. Novo Nordisk's Wegovy (semaglutide 2.4 mg) carries a similar list price of approximately $1,349 per month [2]. The dual GIP/GLP-1 mechanism of tirzepatide produced greater weight loss in head-to-head modeling analyses, which Lilly has used to justify the price point. In SURMOUNT-1 (N=2,539), participants on the 15 mg dose of tirzepatide lost 22.5% of their body weight at 72 weeks, compared to 3.1% with placebo [3]. That degree of weight reduction exceeded what semaglutide 2.4 mg achieved in STEP-1 (N=1,961), where the mean loss was 14.9% at 68 weeks [4].

The clinical efficacy is clear. The financial barrier is equally clear for anyone paying out of pocket.

Tennessee Medicaid: No Coverage for Weight Management

Tennessee's Medicaid program, TennCare, does not cover Zepbound for chronic weight management. Coverage is restricted to tirzepatide's type 2 diabetes indication, marketed under the brand name Mounjaro [5]. This exclusion applies statewide and affects roughly 1.7 million TennCare enrollees.

The distinction matters because tirzepatide is the same molecule in both products. Zepbound is the obesity-indication brand; Mounjaro is the diabetes-indication brand. TennCare will reimburse Mounjaro for patients with a documented A1c ≥7.0% and a type 2 diabetes diagnosis, but a BMI of 35 alone does not qualify.

This coverage gap is not unique to Tennessee. As of early 2026, fewer than half of state Medicaid programs cover any anti-obesity medication for weight management. The Treat and Reduce Obesity Act, reintroduced in Congress, would mandate Medicare Part D coverage of anti-obesity drugs and could influence state Medicaid formulary decisions, but it has not passed as of this writing.

Patients on TennCare who have both obesity and type 2 diabetes should discuss the Mounjaro route with their prescriber. For those with obesity alone, TennCare offers no current pathway to tirzepatide.

Commercial Insurance Coverage in Tennessee

Coverage varies by plan, but several major insurers operating in Tennessee have added Zepbound to their formularies with prior authorization requirements. BlueCross BlueShield of Tennessee (BCBST), the state's largest commercial insurer, covers Zepbound on select plans with step therapy requiring documented failure of lifestyle intervention [6].

Cigna, UnitedHealthcare, and Aetna plans in Tennessee each set their own criteria. Common prior authorization requirements include:

• BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea)
• Documentation of 3 to 6 months of structured diet and exercise without adequate weight loss
• No concurrent use of another GLP-1 receptor agonist
• Prescriber must be an MD, DO, NP, or PA

Even with formulary coverage, tiered copays can be steep. Zepbound often lands on Tier 4 or specialty tiers, generating copays of $150 to $500 per month before any manufacturer assistance. Patients should request a formulary exception or tier reduction if the copay exceeds affordability. Tennessee insurance regulations permit appeals for non-formulary or high-tier drugs when medical necessity is documented.

Dr. Caroline Apovian, a former co-chair of The Obesity Society's clinical guidelines committee, has stated: "Insurance barriers to anti-obesity medications remain the single largest obstacle to closing the treatment gap. The medications work. The question is whether patients can afford to stay on them."

The Eli Lilly Savings Card: How It Works in Tennessee

Eli Lilly offers the Zepbound Savings Card for commercially insured patients. The card reduces out-of-pocket costs to as low as $25 per month, with a maximum benefit of $150 per fill. Patients with commercial insurance that covers Zepbound at any level can activate the card online or through their prescriber's office.

Key rules for 2026:

• The card is not valid for patients on government insurance (Medicare, Medicaid, Tricare, VA)
• Patients must have commercial or employer-sponsored insurance
• The card covers the gap between insurance reimbursement and the patient's copay, up to the monthly cap
• Refills are limited to a 13-fill maximum per calendar year

For uninsured Tennessee patients, Lilly also runs the Zepbound direct purchase program through LillyDirect, where single-dose vials are available at reduced prices compared to the auto-injector pen. Single-dose vials of Zepbound were priced at $399 for a 4-week supply as of early 2026, a meaningful reduction from the $1,059 pen price, though still a significant monthly expense for patients paying cash.

Tennessee has no state-level prescription assistance program specific to anti-obesity medications, so the Lilly card and LillyDirect represent the primary manufacturer-sponsored options.

Compounded Tirzepatide in Tennessee: Legal, Available, and Cheaper

Licensed 503A compounding pharmacies in Tennessee can legally prepare tirzepatide formulations. This remains the most affordable route for cash-pay patients, with prices averaging $249 per month in 2026.

The regulatory background: the FDA placed tirzepatide on its drug shortage list in 2023, which activated a provision under Section 503A of the Federal Food, Drug, and Cosmetic Act allowing compounding pharmacies to prepare copies of drugs in shortage [7]. Tirzepatide was removed from the shortage list in late 2024, and the FDA announced enforcement discretion periods for compounders to wind down production. Legal challenges from compounding pharmacy trade groups have extended this period, and as of May 2026, 503A pharmacies with valid prescriptions continue to dispense compounded tirzepatide in Tennessee.

Important distinctions between compounded and brand-name tirzepatide:

• Compounded versions are not FDA-approved products
• Potency, sterility, and consistency depend on the compounding pharmacy's quality controls
• The Tennessee Board of Pharmacy licenses and inspects 503A pharmacies, but oversight intensity varies
• Patients should verify their pharmacy holds a current Tennessee 503A license and undergoes third-party testing

The price difference is substantial. At $249 versus $1,059 per month, compounded tirzepatide saves roughly $9,720 annually. For many Tennessee patients without insurance coverage, this is the difference between accessing treatment and going without.

Dr. Fatima Cody Stanford, an obesity medicine physician at Massachusetts General Hospital, has noted: "Compounded GLP-1 medications have filled an access gap that the healthcare system created. The tension between affordability and regulatory oversight is real, and patients deserve transparency about what they are receiving."

Telehealth Prescribing: Tennessee Permits It

Tennessee law permits prescribing Zepbound and compounded tirzepatide via telehealth. The Tennessee Board of Medical Examiners allows prescribers to initiate controlled and non-controlled medications through synchronous audio-video visits, provided a valid patient-provider relationship is established [8].

Several telehealth platforms operating in Tennessee prescribe tirzepatide:

• HealthRX partners with Tennessee-licensed prescribers for tirzepatide consultations
• Ro, Hims, and Found operate in Tennessee with varying formulary options
• Some platforms prescribe brand-name Zepbound; others route to compounded tirzepatide

Telehealth visits typically cost $50 to $150 for the initial consultation. Follow-up visits may be bundled into monthly subscription models. Patients should confirm that the telehealth provider uses Tennessee-licensed clinicians and that the pharmacy dispensing the medication holds appropriate state licensure.

One advantage of telehealth for Tennessee patients outside Nashville, Memphis, Knoxville, and Chattanooga: access to obesity medicine specialists is limited in rural counties. Only 2.3% of U.S. physicians are board-certified in obesity medicine, and they concentrate in urban centers [9]. Telehealth eliminates the geographic barrier entirely.

Comparing All Tennessee Pricing Paths

The total annual cost of tirzepatide in Tennessee varies dramatically depending on the access route. A patient with strong commercial insurance and the Lilly savings card may pay $300 per year. A cash-pay patient filling brand-name Zepbound at retail pays $12,708 per year. Here is how the options compare:

Brand-name Zepbound with commercial insurance + Lilly savings card: $25 per month ($300 per year). Requires commercial coverage and savings card activation. This is the lowest-cost path.

Brand-name Zepbound with commercial insurance, no savings card: $150 to $500 per month ($1,800 to $6,000 per year). Depends on formulary tier and plan design.

Brand-name Zepbound cash pay: $1,059 per month ($12,708 per year). No insurance applied. Full WAC.

LillyDirect single-dose vials: $399 per month ($4,788 per year). Available to all patients. Auto-injector pen not included.

Compounded tirzepatide (503A pharmacy): $249 per month ($2,988 per year). Requires a valid prescription. Not an FDA-approved product.

The spread between cheapest and most expensive is over $12,000 annually. Route selection is not a minor decision.

What Affects Your Out-of-Pocket Price

Several factors determine what a Tennessee patient actually pays for Zepbound. Understanding these variables helps patients anticipate costs before filling the first prescription.

Deductible status. Many commercial plans place Zepbound under the medical or pharmacy deductible. A patient with a $3,000 deductible who has not met it will pay full price until the threshold is reached. The Lilly savings card does not apply toward deductible accumulation on most plans.

Accumulator adjuster programs. Some Tennessee employer plans use copay accumulator programs that prevent manufacturer savings card payments from counting toward the annual out-of-pocket maximum. Tennessee has not passed accumulator adjuster reform legislation as of 2026, unlike states such as Virginia and Arizona that cap this practice [10].

Dose escalation timeline. Zepbound's dosing schedule starts at 2.5 mg weekly for four weeks, increases to 5 mg for another four weeks, and then may escalate to 10 mg or 15 mg based on tolerability and response [1]. Because all doses cost the same at list price, dose escalation does not change the monthly cost. But some insurance plans require re-authorization at higher doses, which can create gaps in coverage.

Pharmacy selection. Specialty pharmacies may offer different copay structures than retail chains. Some Tennessee patients report lower copays when filling through mail-order specialty pharmacies designated by their plan.

Clinical Value: What the Evidence Shows

The price tag buys access to one of the most effective anti-obesity medications available. SURMOUNT-1 demonstrated that tirzepatide 15 mg produced a mean weight reduction of 22.5% (approximately 52 pounds from a baseline of 231 pounds) over 72 weeks [3]. The 10 mg dose achieved 19.5%, and the 5 mg dose achieved 15.0%.

Beyond weight, tirzepatide improved cardiometabolic markers. In SURMOUNT-1, waist circumference decreased by 19.4 cm in the 15 mg group. Systolic blood pressure dropped by 7.2 mmHg. Triglycerides fell by 25.6%. These are not trivial secondary endpoints; they translate to reduced cardiovascular risk over time.

The SURMOUNT-2 trial (N=938) focused on patients with both obesity and type 2 diabetes. At 72 weeks, the 15 mg dose produced 14.7% weight loss and a 2.1 percentage point reduction in A1c [11]. For patients carrying both diagnoses, the dual benefit of weight reduction and glycemic control from a single weekly injection simplifies treatment.

The American Association of Clinical Endocrinology (AACE) 2023 obesity algorithm positions tirzepatide as a first-line pharmacotherapy option for patients with BMI ≥30 or BMI ≥27 with complications, alongside semaglutide 2.4 mg [12]. The choice between the two often comes down to insurance coverage, tolerance profile, and patient preference rather than efficacy differences.

Steps to Minimize Your Cost in Tennessee

Patients in Tennessee can follow a specific sequence to find their lowest price:

1. Check your insurance formulary. Call the number on your insurance card and ask whether Zepbound has a pharmacy benefit, what tier it sits on, and what the prior authorization requirements are.

2. Get your prescriber to submit prior authorization early. PA processing takes 5 to 14 business days for most Tennessee plans. Starting before the first fill avoids delays.

3. Activate the Lilly savings card at zepbound.lilly.com if you have commercial insurance.

4. If denied by insurance, file an appeal. Include BMI documentation, comorbidity records, and a letter of medical necessity from your prescriber.

5. If uninsured or if insurance does not cover Zepbound, ask your prescriber about compounded tirzepatide from a Tennessee-licensed 503A pharmacy or explore LillyDirect vials.

6. If you have TennCare and type 2 diabetes, ask your prescriber about Mounjaro (same active ingredient, diabetes indication) as a covered alternative.

A structured approach saves time and money. Most patients who end up paying full retail price simply did not exhaust the available pathways first.